{
  "id": 5593587,
  "title": "Trailing rivals, AbbVie scores win with dual-acting myeloma drug",
  "url": "https://urgent.news/2026/09/04/trailing-rivals-abbvie-scores-win-with-dual-acting-myeloma-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-04T16:00:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/abbvie-multiple-myeloma-etentamig-phase-3-trial-results/829672/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}